PATENT CLAIM ANALYSIS

Application Number: 16147153
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "451000"]

Abstract:
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.

Claim (Index 59):
An oral pharmaceutical composition for oral administration to a subject born with single ventricle heart disease who has undergone Fontan surgery for improving the subject's exercise capacity or increasing the likelihood of improving the subject's exercise capacity, wherein the subject's exercise capacity is indicative of the subject's health following the Fontan surgery, said oral pharmaceutical composition comprising:\n a therapeutically effective amount of udenafil, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, for improving the exercise capacity or increasing the likelihood of improving the subject's exercise capacity; wherein, the therapeutically effective amount of udenafil, or a pharmaceutically acceptable salt thereof, is at least about 125 mg; and wherein, the subject is a human subject.

Metadata:
- Claim Count in Document: 113.0
- Percentile: 97.0
- Lexical Diversity: 1.04
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15887523', '14788211', '15197209', '14079548', '15671653']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7171982948508956
- 35 USC 102 Novelty (BERT): 0.67051300858356
- Combined Prediction Score: 0.712529766224162
- Mean Citation Score: 447.53735599999993
- Max Citation Score: 837.41754
- Similarity Product: 624.3355294329965

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test